Levy R J, Lian J B
Clin Pharmacol Ther. 1979 May;25(5 Pt 1):562-70. doi: 10.1002/cpt1979255part1562.
The urinary excretion of gamma-carboxyglutamic acid (Gla), the amino acid involved in the vitamin K-dependent calcium binding of prothrombin and clotting factors VII, IX, and X, was studied in warfarin-anticoagulated patients. An isotope dilution procedure was developed for the measurement of free urinary Gla with the use of prior anion-exchange chromatography to separate and concentrate the free Gla from whole urine and subsequent automated amino acid analysis. Eight subjects on stable warfarin anticoagulant therapy and 11 comparable control subjects with normal coagulation were examined. Urinary Gla excretion was reduced in patients on warfarin anticoagulant therapy (p = 0.001) and the urinary Gla level correlated (r = -0.73, p = 0.001) with plasma prothrombin time. It is concluded that decreased urinary Gla in warfarin-treated patients is related to coagulation status and may be a clinically useful parameter.
在接受华法林抗凝治疗的患者中，对参与凝血酶原以及凝血因子VII、IX和X的维生素K依赖性钙结合的氨基酸γ-羧基谷氨酸（Gla）的尿排泄情况进行了研究。开发了一种同位素稀释程序，用于测量游离尿Gla，该程序先采用阴离子交换色谱法从全尿中分离并浓缩游离Gla，随后进行自动氨基酸分析。对8名接受稳定华法林抗凝治疗的受试者和11名凝血功能正常的对照受试者进行了检查。接受华法林抗凝治疗的患者尿Gla排泄减少（p = 0.001），且尿Gla水平与血浆凝血酶原时间相关（r = -0.73，p = 0.001）。得出的结论是，华法林治疗患者尿Gla降低与凝血状态有关，可能是一个具有临床实用价值的参数。
